Sentinel node staging of resectable colon cancer: Results of a multicenter study

Annals of Surgery

Volumn 240, Issue 4, 2004, Pages 624-630

  Bertagnolli, Monica ^a,h   Miedema, Brent ^b   Redston, Mark ^a   Dowell, Jeannette ^c   Niedzwiecki, Donna ^c   Fleshman, James ^d   Bem, Jiri ^e   Mayer, Robert ^f   Zinner, Michael ^a   Compton, Carolyn ^g   Wong, W Douglas ^h   Greene, Frederick L ^h   Leong, Stanley P L ^h   Ross, Merrick I ^h  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c DUKE UNIVERSITY   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g MCGILL UNIVERSITY   (Canada)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

ISOSULFAN BLUE;

AGED; CANCER STAGING; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT CARE; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; SENTINEL LYMPH NODE; TISSUE SECTION; UNITED STATES;

AGED; COHORT STUDIES; COLECTOMY; COLONIC NEOPLASMS; COLORING AGENTS; FALSE NEGATIVE REACTIONS; FEASIBILITY STUDIES; FEMALE; FORECASTING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RISK ASSESSMENT; ROSANILINE DYES; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SIGMOID NEOPLASMS; SINGLE-BLIND METHOD;

EID: 4644352802     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000140753.41357.20     Document Type: Conference Paper

References (21)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Liefers G-J, Cleton-Jansen A-M, van de Velde CJH, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med. 1998;339:223-228.
3. Sanchez-Cespedes M, Esteller M, Hibi K, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res. 1999;5:2450-2454.
4. Morton DL, Thompson JF, Essner R, et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg. 1999;230:453-463.
5. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222:394-399.
6. Bilchik AJ, Saha S, Wiese D, et al. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol. 2001;19:1128-1136.
7. Bilchik AJ, Nora DT, Sobin LH, et al. Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol. 2003;21:668-672.
8. Merrie AEH, van Rij AM, Phillips LV, et al. Diagnostic use of the sentinel node in colon cancer. Dis Colon Rectum. 2001;44:410-417.
9. Saha S, Bilchik A, Wiese D, et al. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique: a multicenter trial. Ann Surg Oncol. 2001;8(suppl):94S-98S.
10. Saha S, Dan AG, Berman B, et al. Lymphazurin 1% versus 99mTc sulfur colloid for lymphatic mapping in colorectal tumors: a comparative analysis. Ann Surg Oncol. 2004;11:21-26.
11. Tschmelitsch J, Klimstra DS, Cohen AM. Lymph node micrometastases do not predict relapse in stage II colon cancer. Ann Surg Oncol. 2000;7:601-608.
12. Kitagawa Y, Watenabe M, Hasegawa H, et al. Sentinel node mapping for colorectal cancer with radioactive tracer. Dis Colon Rectum. 2002;45:1476-1480.
13. Joosten JJ, Strobbe LJ, Wauters CA, et al. Intraoperative lymphatic mapping and the sentinel node concept in colorectal carcinoma. Br J Surg. 1999;86:482-486.
14. Bilchik AJ, Saha S, Tsioulias GJ, et al. Aberrant drainage and missed micrometastases: the value of lymphatic mapping and focused analysis of sentinel lymph nodes in gastrointestinal neoplasms. Ann Surg Oncol. 2001;8(suppl):82S- 85S.
15. Wood TF, Saha S, Morton DL, et al. Validation of lymphatic mapping in colorectal cancer: in vivo, ex vivo, and laparoscopic techniques. Ann Surg Oncol. 2001;8:150-157.
16. Evangelista W, Satolli MA, Malossi A, et al. Sentinel lymph node mapping in colorectal cancer: a feasibility study. Tumor. 2002;88:37-40.
17. Paramo JC, Summerall J, Poppiti R, et al. Valideation of sentinel node mapping in patients with colon cancer. Ann Surg Oncol. 2002;9:550-554.
18. Tsioulias GJ, Wood TF, Morton DL, et al. Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms. Arch Surg. 2000;135:926-932.
19. Bendavid Y, Latulippe JF, Younan RJ, et al. Phase I study on sentinel lymph node mapping in colon cancer: a preliminary report. J Surg Oncol. 2002;79:81-84.
20. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22.
21. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21:2912-2919.